Bioventix PLC (AIM: BVXP)

Market Cap	207.48M
Revenue (ttm)	13.60M
Net Income (ttm)	8.67M
Shares Out	5.22M
EPS (ttm)	1.63
PE Ratio	24.35
Forward PE	23.01
Dividend	1.52 (3.82%)
Ex-Dividend Date	Apr 11, 2024

Volume	4,447
Open	3,900.00
Previous Close	3,950.00
Day's Range	3,900.00 - 4,050.00
52-Week Range	3,402.00 - 5,100.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2024

About Bioventix

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 12
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: BVXP

Financial Performance

In 2023, Bioventix's revenue was 12.82 million, an increase of 9.36% compared to the previous year's 11.72 million. Earnings were 8.37 million, an increase of 9.10%.